Please login to the form below
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.
Summary/transcript
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.The primary endpoint was PFS and the researchers observed a PFS benefit that they think is “clinically relevant and statistically significant,” as Dr Toni Choueiri of the Dana-Farber Cancer Institute highlights. Further, there was a 31% decrease in risk of progression of death. Also, the secondary endpoint, response rate, was higher and more significant with cabozantinib. Dr Choueiri, who presented the results at ESMO 2016, explains, they also had an early look at overall survival (OS), which is not significant yet but trending in the right direction.
The side effects were similar in both arms and in our interview, Dr Choueiri poses the question if cabozantinib could become the next first-line option after sunitinib, which was the standard and most used first-line agent for ten years. He believes that cabozantinib could become the next first-line option and therefore “it is very possible that this study will change how we treat frontline renal cell cancer”.
If you would like to discover how we can leverage our network of relationships and understanding of the oncology landscape and stakeholders, to shape content and amplify messages across relevant audiences, channels and communities please contact either Stephen Dunn or Charlie Grieve on 020 7291 5070, we’d be delighted to hear from you.
Company Details
Brandcast Health
+44 (0)20 7291 5070
Address:
16-17 Little Portland Street
London
W1W 8BP
Latest content on this profile
- Ansar Jawair discusses precision medicines - what they are, where we are today and their future
- Ansar Jawair, Founder and CEO of Precision Medicines Ltd, tells us about his talk on precision medicines, what they are, where we are today, the future and some of the challenges involved in their implementation to patients. Precision medicines are matched to patients using biomarkers, enabling to target the specific drivers of various cancers. Major advances have already been made in this field, treating a range of cancers. Some of the major challenges include working with the complexities in different countries, trying to establish diagnostic testing, for enabling precision medicine. He mentions how we are moving towards an era of delivering personalised treatments that are matched to the individual patient. Furthermore, through advances in precision medicines and in diagnostic testing, we are seeing earlier detection of disease and identification of risk factors, allowing for preventative measures.
Brandcast Health
- Oradit Ido talks about the Unique Israeli Entrepreneurial Ecosystem
- Orado provides an overview of why she believes Israel is unique in its approach to innovation. With a history of overcoming challenges, a people who pride themselves on their chutzpe (audaciousness), and a fast paced culture, she explains why she thinks Israel provides a perfect ecosystem for innovation and entrepreneurship. She explains that within medicine and healthcare, there is a need for strategic support and engagement, and as an example of how the government is supporting this she provides an overview of the Ministry of Health challenge tender programme.
Brandcast Health
- Acute leukaemia patients get new online information centre that will help them get the best possible care
- A unique collaboration between some of the world's leading leukaemia experts and the patient community in the UK and across Europe has resulted in the development of a one-of-a-kind educational resource centre that provides acute leukaemia patients with the support they need, when they need it most.
It is the first time that such a comprehensive medical information video resource has been gathered together in this format and comes at a time when cancer patients and caregivers are advocating for a bigger say in decisions about their individual treatment regimens.
Brandcast Health
- Aubrey De Grey provides a summary of his goal of combating ageing
- Aubrey believes ageing is a serious issue, not only because people die of old age, but because it causes suffering. He discusses the fact that many diseases including chronic cancer, are the result of ageing and that by tackling ageing of cells, we can address many of the issues associated with poor health. To find out more about Aubrey and the SENS Research Foundation visit: http://www.sens.org/
Brandcast Health
- Oradit Ido talks about the Unique Israeli Entrepreneurial Ecosystem
- Orado provides an overview of why she believes Israel is unique in its approach to innovation. With a history of overcoming challenges, a people who pride themselves on their chutzpe (audaciousness), and a fast paced culture, she explains why she thinks Israel provides a perfect ecosystem for innovation and entrepreneurship. She explains that within medicine and healthcare, there is a need for strategic support and engagement, and as an example of how the government is supporting this she provides an overview of the Ministry of Health challenge tender programme.
Brandcast Health
- HaemOncCam #Haem2016
Brandcast Health
